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Abstract
Introduction: Chemotherapy related encephalopathy is commonly reported with certain forms of
chemotherapy but few reports note an association with low dose 5-Fluorouracil.
Case presentation: A 57-year-old Caucasian lady received her first cycle of Cisplatin and
5-Fluorouracil for palliative treatment of cervical carcinoma, and presented several days later with
signs of encephalopathy. Several causes were eliminated, and encephalopathy related to 5-Fluorouracil
was thought to be the most likely cause. Magnetic Resonance Imaging of the head revealed changes
related to the chemotherapy received. Symptoms resolved completelywithin three days of presentation.
Conclusion: Encephalopathy from low dose 5-Fluorouracil is not well documented in the literature.
Fluid rehydration and supportive treatment is required. Signs and symptoms resolved completely
with no residual effects on follow up.
Introduction
Certain types of chemotherapy are more commonly
associated with neurotoxic side effects, most commonly
Ifosfamide and Methotrexate [1]. High doses of
5-Fluorouracil have been reported to cause neurological
signs and symptoms, but only a few cases of encephalo-
pathy have been recorded when low doses, or boluses, of
5-Fluorouracil have been used [2,3].
Fluorouracil is an analogue of fluorinated pyramidine
commonly used in the treatment of several cancers. After
rapid intravenous injection, fluorouracil rapidly diffuses
into all body compartments, including the nervous
system. The drug is primarily degraded by the liver. The
toxicity of 5-FU is strongly influenced by the dosage used
and the rate and duration of drug administration.
Neurological toxicity manifested by somnolence, confu-
sion, seizures, cerebellar ataxia and rarely encephalopathy
are known but uncommon. They are usually totally
reversible on withdrawal of the drug. Leucovorin which
is commonly combined with 5-FU enhances the anti-
tumour activity as well as toxicity [5].
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Case presentation
A 57-year-old Caucasian lady was admitted to hospital
feeling generally unwell with nausea, lethargy and reduced
appetite. She had been unwell since discharge from
hospital two weeks ago after her first in-patient cycle of
Cisplatin and 5-Fluorouracil (5-FU). She was diagnosed
with FIGO (International Federation of Gynaecologists
and Obstetricians) Stage IVb mucinous adenocarcinoma
of the endocervix seven months previously, an incidental
finding after a laparotomy and hysterectomy were
performed for abdominal distension. No other metastases
were found at the time, but a relapse in the vaginal vault
and small bowel were identified on repeat laparotomy.
She proceeded to external beam radiotherapy (45 Gy/25
Fractions over five weeks) to the pelvis with concurrent
Cisplatin, 40mg/sqm. During this period of treatment, she
developed a thrombus in the inferior mesenteric vein and
was treated with low molecular weight heparin. Blood
counts and biochemical profile were normal throughout
chemoradiation. In-patient chemotherapy was started one
month after completing radiotherapy, consisting of
Cisplatin (75 mg/sqm) and 5-FU (1 g/sqm), as a four
day cycle.
A past medical history of Peutz-Jegher’s syndrome,
diagnosed at the age of 17, resulted in three bowel
operations over two decades, leaving her with an
ileostomy. She also had a history of breast cancer
25 years ago, for which a left mastectomy, axillary node
sampling and a bilateral oophorectomy were performed.
No further radiotherapy, chemotherapy or Tamoxifen was
given. Drug history was insignificant.
She presented to hospital two weeks after the first cycle of
Cisplatin and 5-FU, feeling unwell. She was dehydrated
with renal impairment; urea was 12.8 mmol/l and
creatinine 154 mmol/l. Other biochemical markers,
including calcium, potassium and magnesium were
normal, and C-reactive protein (CRP) was 3 mg/l,
haemoglobin 10.5 g/dL, Sodium 141 mmol/l.
Rehydration continued over the next few days. She
remained apyrexial with oxygen saturations of 98-100%
on room air.
Three days after admission, the patient described an
episode of brief confusion in the morning. Renal function
was improving and biochemistry remained normal with a
CRP of 4 mg/l. Later the same day and into the early hours
of the morning, her confusion returned and she became
incontinent of urine. She no longer communicated with
staff verbally, and repetitive actions, such as licking her lips
and moving her hand round in circles, were observed. She
showed no aggressive or disruptive behaviour, but refused
to have bloods taken or a cannula inserted by pushing staff
away. No prior mental health issues were noted in hospital
records or from family.
She was no longer orientated in time, place or person. Her
abbreviated mental test score (AMTS) was 0 out of 10 and
repetitive movements of her right arm continued. Her
temperature was 37°C, chest remained clear on examina-
tion, abdomen soft with bowel sounds present. Glasgow
Coma Score (GCS) was 14/15. Random blood glucose was
within normal limits and urine dipstick was negative.
Blood tests were repeated and sent for full blood count,
biochemical profile, CRP and blood culture. A CT head
was booked urgently and she was commenced on
Dexamethasone 4 mg twice a day.
Night review by the on-call doctor found the patient
groaning and making incomprehensible sounds and
thrashing around. Repetitive movements continued but
no seizure activity was noted. Midazolam and Lorazepam
were given with minimal benefit.
Biochemistry remained normal, blood cultures were
negative, with a normal thyroid stimulating hormone
(TSH), normal calcium, potassium and magnesium and
CRP of 8 mg/l, haemoglobin 10.6 g/dL, white cell count
6.1 × 109/l, sodium 143 mmol/l. Autoantibody screen
was negative and electrophoresis showed no qualitative
abnormality.
CT scan of the head with contrast was conducted, which
reported no sign of intra- or extra-cranial abnormality.
The following day, day six of admission, the patient was
found to be smiling and lucid. She was orientated in time,
place and person. The Neurology team were asked to
advise and their differential diagnosis consisted of non
convulsive status, acute mal encephalitis, paraneoplastic
limbic encephalitis, drug related encephalopathy, sinus
vein thrombosis or infectious encephalitis. They suggested
the following further investigations; MRI brain, to exclude
temporal lobe inflammation, lumbar puncture, to assess
for infection or neoplastic infiltration, and an EEG.
The patient was much improved. She was eating and
drinking, communicating normally with staff and her
husband, with no obvious immediate adverse effect of the
acute confusional state. Her renal function remained
impaired, but all other bloods were normal.
Unfortunately, patient consent could not be obtained for a
lumbar puncture or an EEG, despite emphasis given to
their importance. At the time of asking, the patient had
improved and was deemed to have capacity.
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The MRI concluded that there were small amounts of
non-enhancing white matter change in the parietal lobes
(Figure 1 and Figure 2).
Discussion
Given the unlikelihood of metastatic disease, sepsis or a
severe metabolic disorder causing the acute confusion, we
assessed the likelihood of the events being caused by
chemotherapy, in particular, 5-FU.
Several cases of chemotherapy related encephalopathy are
noted in the literature, with some agents being more
problematic than others. Neurotoxicity is a major
limitation of many drugs used in cancer patients, and
as more and more chemotherapy agents are being added
to the list, physicians must be wary of any signs of
neurotoxicity after chemotherapy cycles [1]. Magnetic
resonance imaging makes recognition of central nervous
system toxicity easier [4].
Ifosfamide related encephalopathy is well known [1],
occurring in 15-30% of patients treated with the che-
motherapy agent. Symptoms of encephalopathy can arise
soon after receiving combination chemotherapy involving
Ifosfamide for different tumours [5]. Patients often recover
after discontinuation of the agent. The administration of
methylene blue (methylthioninium chloride) has little
evidence as an antidote [6].
Another chemotherapy agent of interest is Methotrexate,
which forms the mainstay of treatment for patients with
osteosarcoma. It is also a major cause of treatment related
acute neurotoxicity, especially at the high doses which it is
prescribed [1]. Cases have been noted to cause white
matter injury on MRI at the time of symptoms, which do
not show contrast enhancement. Such injuries appear to
resolve on follow up scans [7].
The significance of hyperammonaemic encephalopathy as
a cause for neurological deterioration post chemotherapy
has also been reported. Characteristics include sudden
alteration in mental status accompanied by markedly
elevated plasma ammonia levels in the absence of obvious
liver disease or any other identifiable cause. More
importantly, it is known to occur in solid organ
malignancies treated with 5-Fluorouracil [2,8].
Cisplatin has also been noted to cause neurological
symptoms, most commonly a peripheral sensory neuro-
pathy; however, encephalopathy and seizures have also
been observed, especially following rechallenge with the
Figure 1. Magnetic Resonance Imaging showing white matter
changes in the parietal area post gadolinium enhancement.
Figure 2. Magnetic Resonance Imaging showing nothing
remarkable pre enhancement.
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Platinum agent [9,10]. More commonly however, toxicity is
related to hypomagnesaemia and hypokalaemia and in
cases of rapid increases in blood pressure, such as renal
disease or hypertensive encephalopathy, where such con-
ditions can exacerbate the ensuing encephalopathy [11].
Doses of Cisplatin must be adjusted in cases of renal failure
due to cumulative nephrotoxicity. In this case, considera-
tion must be given to the impaired renal function which
may have contributed to the neurological symptoms by
enhancing the effects of Cisplatin; however, renal function
at the time of administration of chemoradiotherapy and the
first cycle of Cisplatin/5-FU was normal, and given no
previous side effects or nephrotoxicity were observed with
Cisplatin when given with concurrent radiotherapy for five
weeks, it is unlikely that the renal impairment or the
neurotoxicity were due to Cisplatin.
Cases have commonly reported high dose 5-FU induced
encephalopathy, [12,13] but encephalopathy associated
with lower doses is less common. Our patient received a
total of 4000 mg/sqm over a four day period, 1000 mg/
sqm daily, a relatively low dose of 5-FU. In comparison,
several case reports have linked symptoms of encephalo-
pathy with daily high doses of 1500 mg or higher.
Reported cases of low dose encephalopathy are rare. The
few that have been reported note the absence of structural
abnormalities, but do show an association with hyper-
ammonaemia in specific cases [2,3]. The significance of
the raised ammonia level is yet to be uncovered. Patients
present with encephalopathy, including confusion, cogni-
tive dysfunction, disorientation, agitation, lethargy, sei-
zure, cerebellar ataxia, nystagmus and coma [2,3].
Diagnostic criteria include 1. Development of encephalo-
pathy during or shortly after completion of 5-FU therapy;
2. Exclusion of other metabolic or physical factors that
may effect level of consciousness; 3. Exclusion of drug
effect by concomitant medications [3]. An important point
to make in such a situation, is the possibility of a deficit in
dihydropyrimidine dehydrogenase (DPD). DPD is the
initial and rate-limiting enzyme in the catabolism of 5-FU.
More than 80% of administered 5-FU is eliminated by
DPD, therefore implying that a deficiency in the enzyme
would result in highly toxic effects such as severe
mucositis, myelosuppression/neutropenia and severe diar-
rhoea. Encephalopathy and hepatitis are noted to be rarer
manifestations of toxicity as a result of enzyme deficiency.
Only one of the reported cases of 5-FU induced
encephalopathy measured DPD levels using PCR, which
increased after administration of 5-FU, therefore suggest-
ing an unlikely DPD deficiency [2]. It is thought that DPD
deficiency in our patient is unlikely, given the lack of any
of the other severe toxic effects such as mucositis or
neutropenia being present. Malnutrition and thiamine
deficiency are also thought to contribute to this neurolo-
gical syndrome [3].
Conclusion
Few cases have been documented, but in most, neurolo-
gical features are transient and recovery often complete.
This patient made a complete recovery after the solitary
episode of confusion, and is doing well with no residual
symptoms three weeks on from presentation. Given her
reaction to chemotherapy, a decision was taken to not
attempt a rechallenge of 5-Fluorouracil in this patient.
Recognition of such cases is imperative in order to
maximise treatment after exclusion of all other possible
causes.
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